Form 4: Cadrenal CFO Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Cadrenal Therapeutics' CFO, Matthew K. Szot, sold 3,600 shares of common stock for $13.99 per share through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of common stock.
- A total of 3,600 shares were sold across two transactions on October 24, 2025, and October 27, 2025.
- Each transaction involved the sale of 1,800 shares at a price of $13.99 per share.
- These sales were conducted in accordance with a Rule 10b5-1 trading arrangement adopted by Mr. Szot on May 9, 2025.
- Following the transaction on October 24, 2025, Mr. Szot beneficially owned 11,733 shares.
- After the transaction on October 27, 2025, his beneficial ownership decreased to 9,933 shares.
Sentiment
Score: 4
Explanation: The sale of shares by a Chief Financial Officer, even under a pre-arranged 10b5-1 plan, generally carries a slightly negative to neutral sentiment as it reduces insider ownership. However, the pre-planned nature mitigates concerns compared to an ad-hoc sale.
Negatives
- The Chief Financial Officer's beneficial ownership of common stock decreased by 3,600 shares, which could be perceived as a reduction in insider alignment.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders may interpret the reduction in insider ownership as a signal, potentially influencing market perception of the stock.
Key Dates
| Date | Description |
|---|---|
| 05/09/2025 | Date the Rule 10b5-1 trading arrangement was adopted by Matthew K. Szot. |
| 10/24/2025 | Date of the first reported transaction where 1,800 shares of common stock were sold. |
| 10/27/2025 | Date of the second reported transaction where 1,800 shares of common stock were sold. |
| 10/28/2025 | Date the Form 4 was signed by Matthew K. Szot. |
Recommendation
holdThe reported transactions are sales of common stock by the Chief Financial Officer under a pre-arranged Rule 10b5-1 trading plan. While insider selling can sometimes be viewed negatively, the pre-planned nature suggests the decision was made in advance and is not necessarily indicative of a change in the officer's outlook on the company's immediate prospects. Without additional context on the company's financial performance or strategic direction, these transactions alone do not warrant a strong buy or sell recommendation, thus a 'hold' stance is appropriate.
Keywords
Cadrenal Therapeutics, CVKD, Form 4, Insider Trading, Stock Sale, Matthew K. Szot, Chief Financial Officer, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.